Tempus Unveils the Next-Generation of Lens, Expanding Its Agentic AI Platform for Oncology Drug Development
Tempus AI launched the next‑generation Lens, an agentic AI platform that unifies its multimodal real‑world oncology data, high‑performance computing and validated AI agents. The cloud‑based system lets drug developers create research plans in plain language, execute analyses on more than 8.5 million de‑identified patient records, and receive reproducible, code‑backed results within minutes. Lens is already deployed by 19 of the top 20 biopharma companies, aiming to speed trial design, biomarker validation and patient‑subgroup targeting. The platform is commercially available at lens.tempus.ai.
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Pfizer reported that its BRAFTOVI (encorafenib) regimen combined with cetuximab and FOLFIRI halved the risk of disease progression or death in patients with BRAF V600E‑mutant metastatic colorectal cancer. Median progression‑free survival more than doubled to 15.2 months versus 8.3 months for...
Kelonia Therapeutics Presents Updated First-in-Human Data From Phase 1 inMMyCAR Study of KLN-1010 in Vivo BCMA CAR-T Therapy at the...
Kelonia Therapeutics reported updated Phase 1 inMMyCAR data for its in‑vivo BCMA CAR‑T candidate KLN‑1010 at ASCO 2026. All 18 patients dosed showed a 100% overall response rate with MRD‑negative bone marrow, and the earliest‑treated patient remains disease‑free beyond ten months....
ASCO 2026: Bayer Shares New Findings for NUBEQA® (Darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to...
Bayer presented Phase II ARACOG trial data at ASCO 2026 showing that NUBEQA® (darolutamide) significantly limited cognitive decline in men with advanced prostate cancer compared with enzalutamide. Over 24 weeks, the median maximal cognitive domain change was –15.8% for darolutamide versus...
Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of...
Salubris Biotherapeutics presented updated Phase 1/2 data for JK06, a 5T4‑targeted antibody‑drug conjugate, at the 2026 ASCO meeting. The study treated 173 patients across dose‑escalation and expansion cohorts, reporting a 50% objective response rate (ORR) in squamous non‑small cell lung cancer...
Exelixis Announces Results From Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (Cabozantinib) in Non-Functional and Functional Neuroendocrine...
Exelixis presented a subgroup analysis of the phase 3 CABINET trial at ASCO 2026, showing that CABOMETYX (cabozantinib) significantly extends progression‑free survival (PFS) in advanced neuroendocrine tumors (NET) regardless of functional status. In non‑functional NET, median PFS was 9.4 months versus 3.1 months on...
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026
Massive Bio unveiled the next‑generation Reticulum Nexus™ suite at ASCO 2026, integrating six AI‑driven agents—Patient Connect™, TrialRelay™, NexusPulse™ calculators, Sentinel Agents™, DrArturo AI™ and Phoebe AI™—into a real‑time orchestration layer for precision oncology. The platform moves patients from fragmented trial...
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
Tempus AI has launched Tempus Preview, an application that delivers preliminary, clinically relevant biomarker predictions within roughly 24 hours of tissue receipt. The tool focuses initially on high‑impact markers such as MSI‑H, EGFR mutations in NSCLC, and FGFR fusions in hepatobiliary and...
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual...
Immunome presented detailed Phase 3 RINGSIDE data for its gamma secretase inhibitor varegacestat at the 2026 ASCO meeting. The trial met its primary endpoint, showing an 84% reduction in progression‑free survival risk and a 56% objective response rate versus 9% with...
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Summit Therapeutics presented interim Phase II data from the AK112‑206 trial at ASCO 2026, evaluating ivonescimab combined with mFOLFOX6 in treatment‑naïve, microsatellite‑stable metastatic colorectal cancer. In 49 patients, the regimen achieved a 70.8% objective response rate and a disease control...
ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit From Adding Chemotherapy in Metastatic Prostate Cancer
Veracyte’s Decipher Prostate genomic test was shown in the ENZAMET Phase III trial to predict which men with metastatic prostate cancer benefit from adding docetaxel to standard ADT + enzalutamide therapy. Patients with high Decipher scores (>0.85) and high‑volume disease experienced significantly better...
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: A First-in-Class Epigenetic Silencer for Patients with Hepatitis...
Tune Therapeutics reported Phase 1b/2a data for TUNE‑401, an IV‑delivered LNP‑RNA epigenetic silencer, at the EASL 2026 Congress. The study showed dose‑dependent, durable repression of all key HBV biomarkers, including direct loss of cccDNA‑derived pgRNA and HBeAg in a subset of...
Tanner Introduces New AI Voice Chat Assistant to Reduce Call Center Hold Times
Tanner Health has launched Clara, a bilingual AI voice‑chat assistant powered by Hyro, to handle inbound calls 24/7 for its Georgia and Alabama facilities. The system can schedule appointments, manage prescriptions and verify patient identity without human intervention, cutting call‑center...
Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including...
Corcept Therapeutics reported overall survival data from its Phase 3 ROSELLA trial of Lifyorli (relacorilant) plus nab‑paclitaxel in platinum‑resistant ovarian cancer at ASCO 2026. The combination cut the risk of death by 35% (HR 0.65, p = 0.0004) and extended median overall survival to 16.0...
CUPE Blasts Ford Government for $36 Million Budget Deficit at Scarborough Health Network
The Canadian Union of Public Employees (CUPE) representing 2,500 staff at Scarborough Health Network (SHN) blames Ontario’s Ford government for a roughly $27 million USD budget shortfall that threatens further staffing cuts. A November 2025 CUPE survey found 71% of employees...